1 / 7

Jean-Claude Karasi M.D

Assessing the WHO- recommended First-line ART regimens for Resource- limited settings: comparison of the relative virologic efficacy and resistance patterns of TDF/3TC/NVP to AZT/3TC/NVP in a Rwandan Cohort. Jean-Claude Karasi M.D. Cohort description.

aldis
Télécharger la présentation

Jean-Claude Karasi M.D

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Assessing the WHO-recommended First-line ART regimens for Resource-limited settings: comparison of the relative virologicefficacy and resistance patterns of TDF/3TC/NVP to AZT/3TC/NVP in a RwandanCohort Jean-Claude Karasi M.D

  2. Cohort description

  3. Results: Cohort baseline characteristics

  4. Proportion of patients attained the primary endpoint

  5. Proportion of resistance mutations in patients with VL > 1000 copies/ml

  6. Conclusions • In thiscohort, TDF/3TC/NVP was as effective as AZT/3TC/NVP but wasassociatedwithfewer discontinuations due to adverse effects. However, itwasless effective in patients withhighbaselineVL • What could be the optimal first line option for patients with high baseline viral load in resources limited settings where VL monitoring remains a challenge ?

  7. ACKNOWLEDGMENTS • Institutional support • Rwanda Biomedical center • National refferalLaboratory • CRP-Santé • Lux-Development • Ministry of Heallth Rwanda

More Related